- “Our priorities have been clear throughout the pandemic. We want to keep our employees safe, while continuing to serve our customers, who rely on our products and services to manage their conditions. I am proud of the work that is being done by our many teams across the world to make sure that we continue business operations and continue to support our customers,” says
Coloplast CEOKristian Villumsen and continues:
- “Despite the COVID-19 outbreak, we deliver a solid set of results in Q1. We continue to deliver organic growth across all geographical regions and business areas, which means that more and more people with personal medical conditions are getting the help and support they need to lead better lives.”
- “I would like to highlight our solid performance in the US as well as our strong momentum in Emerging Markets, particularly driven by growth in
China ,Latin America and tender deliveries inRussia . Also, our Interventional Urology business delivered a good quarter driven by the Men’s Health portfolio in the US, which returned to growth as elective procedures continued to recover during the quarter.”
Organic growth rates by business area were 6% in Ostomy Care, 6% in Continence Care, 5% in Interventional Urology, and 1% in Wound &
Looking at sales by geography, the European markets contributed with 2% growth, Other developed markets delivered 7% revenue growth, while Emerging Markets provided a 16% increase. Growth in
While
ROIC after tax and before special items was 44% against 47% in the same period last year impacted by the acquisition of Nine Continents Medical in
The COVID-19 pandemic
The company’s global manufacturing sites are operating at normal capacity in terms of production and supply chain, and the company continues to fully meet customer demand.
Financial guidance for 2020/21
In line with its long-term guidance
Capital expenditure is still expected to be DKK ~1.1bn. The effective tax rate is still expected to be ~23%.
CONTACTS
Peter Mønster
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 23
dkpete@coloplast.com
Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com
Financial highlights and key ratios
DKKm | 2020/21 – Q1 | 2019/20 – Q1 | Change |
Revenue | 4,738 | 4,712 | 5% |
EBIT | 1,536 | 1,472 | 4% |
EBIT margin | 32% | 31% | 1%-pts |
Net profit for the period | 1,136 | 1,092 | 4% |
Sales performance by business area
DKKm | 2020/21 - Q1 | 2019/20 - Q1 | Organic growth | Reported growth |
Ostomy Care | 1,932 | 1,907 | 6% | 1% |
Continence Care | 1,705 | 1,686 | 6% | 1% |
Interventional Urology | 536 | 535 | 5% | 0% |
Wound & | 565 | 584 | 1% | -3% |
Net revenue | 4,738 | 4,712 | 5% | 1% |
Sales performance by region
DKKm | 2021/21 – Q1 | 2019/20 – Q1 | Organic growth | Reported growth |
European markets | 2,737 | 2,744 | 2% | 0% |
Other developed markets | 1,174 | 1,178 | 7% | 0% |
Emerging Markets | 827 | 790 | 16% | 5% |
Net revenue | 4,738 | 4,712 | 5% | 1% |
Attachment
- 2020_2021_Q1_PM_ENG
© OMX, source